10 results about "Anisodamine" patented technology

The invention relates to a traditional Chinese medicine composition for improving hypomenorrhea and application thereof, and belongs to the technical field of biological medicine. The herba leonuri, the anisodamine and the Dingkundan are combined to form the composition, efficacy complementation can be achieved, it is guaranteed that the medicine takes effect quickly, the long-acting treatment effect is maintained, meanwhile, the side effect caused by long-term single medication is avoided, the treatment safety and tolerance are improved, the menstrual volume can be remarkably increased, endometrial blood circulation can be improved, and the curative effect is improved. The hypomenorrhea is effectively improved. The medicines in the composition are all approved compliant medicines, the source is clear, the quality is controllable, the administration scheme is simple and easy to implement, the composition is suitable for clinical popularization and application, and a novel safe, efficient and reproducible treatment method is provided for hypomenorrhea.

Use of anisodamine hydrobromide in the preparation of a drug for treating sepsis and / or septic shock. Anisodamine hydrobromide can ameliorate CLP-induced changes in vital signs of rats, improve the morphology of lung tissue, regulate related target proteins, and produce a good therapeutic effect on sepsis and / or septic shock.

A racanisodamine capsule with high dissolution rate and fast disintegration belongs to the technical field of medicine preparation, and through the innovation of narrow distribution micronization of active ingredients, synergistic compatibility of novel auxiliary materials, capsule type adaptation process and the like, the prepared racanisodamine capsule has the dissolution rate of more than or equal to 95% within 30 min and the accelerated test dissolution rate of more than or equal to 92% within 12 months, the auxiliary materials are plant-derived or degradable ingredients, and the process energy consumption is reduced by more than 20%. The invention expands the dosage form applicable population, further improves the drug effect and safety, is energy-saving and environment-friendly, and conforms to the green pharmaceutical trend.

This invention discloses the application of overexpression of transcription factor AbbHLH29 in improving the biological traits of belladonna. By overexpressing AbbHLH29 in belladonna, this invention increases the expression level of the H6H gene, iron content, chlorophyll a content, aboveground biomass, or the content of scopolamine and anisodamine. The nucleotide sequence of AbbHLH29 is shown in SEQ ID No. 11. This research is not only significant in elucidating the molecular mechanism by which AbbHLH29 regulates the biosynthesis of belladonna alkaloids and iron homeostasis, but also provides important technical support for future research on belladonna alkaloid metabolic engineering.

The invention relates to the technical field of medicines, in particular to application of anisodamine hydrobromide. The invention provides new application of anisodamine hydrobromide, and researches show that anisodamine hydrobromide can improve rat vital sign changes caused by CLP, improve lung tissue morphology and regulate related target proteins, so that the anisodamine hydrobromide has a good treatment effect on sepsis and / or septic shock.

The utility model discloses extraction equipment for a gastric spasmolysis drug anisodamine hydrobromide. The extraction equipment comprises a bottom frame, an extraction tank fixedly mounted on one side of the top of the bottom frame, a pressurizing and shunting tank fixedly mounted on one side of the extraction tank, and an electric cabinet fixedly mounted on the top of the bottom frame and positioned between the extraction tank and the pressurizing and shunting tank. And a conveying pump and a material guide pump are fixedly mounted at the bottom of the electric control box on the bottom frame. A material pumping pipe and a material discharging pipe are mounted at the two ends of the material guiding pump respectively, and one end of the material discharging pipe is in butt joint with the extraction tank. The two ends of the delivery pump are in butt joint with the extraction tank and the pressurizing flow dividing tank respectively. Discharging pipes with different heights are installed on the two sides of the pressurizing flow dividing tank in a penetrating mode. According to the utility model, the density of the residual liquid in the pressurized shunting tank is changed according to the adjustment of the pressure intensity. And the sewage passes through the biological filter membrane and is discharged from the cleaning holes. It is guaranteed that no liquid remains in the pressurizing flow dividing tank, and extraction of the next group of medicine is not affected.

The application provides a feruloyl-CoA 6'-hydroxylase pocket mutant and application. The feruloyl-CoA 6'-hydroxylase pocket mutant is obtained by amino acid mutation of the amino acid sequence shown in SEQ ID NO. 1, and includes at least one of the following amino acid mutations: L141N, L141G, A142N, Q144D, F156Y, V157T, N311G. The application also provides an engineering bacterium for synthesizing coumarin compounds by using the feruloyl-CoA 6'-hydroxylase mutant. The feruloyl-CoA 6'-hydroxylase mutant has good enzyme activity and stability, so that the engineering bacterium can not only realize efficient synthesis of coumarin compounds such as scopoletin, aesculin, aesculin glycoside and anisodamine, but also realize efficient de novo biosynthesis of the coumarin compounds, thereby providing a reference for microbial synthesis of the coumarin compounds.

This invention belongs to the field of biomedical technology and discloses a Schisandra chinensis exosome-like vesicle-mediated targeted delivery formulation of anisodamine and its application in preventing and treating alcohol-induced liver injury. This invention provides a drug delivery system that improves the water solubility and dispersibility of drugs (such as anisodamine) through carrier-free self-assembled nanoparticle formulations. Simultaneously, it utilizes plant-derived vesicles (such as Schisandra chinensis) for encapsulation, leveraging the excellent biocompatibility, targeting, and penetration of exosome-like vesicles to enhance drug accumulation and bioavailability in liver tissue. This drug delivery system not only promises to solve key challenges in the clinical application of drugs such as poor water solubility and low bioavailability, but also provides a new technical approach for the efficient delivery of natural active ingredients, holding significant theoretical and practical importance for promoting the development of hangover relief health products and liver injury treatment drugs.

A use of anisodamine or a pharmaceutically acceptable salt thereof in the preparation of a cellular glycocalyx protectant and a use of the anisodamine or the pharmaceutically acceptable salt thereof as a cellular glycocalyx protectant in the restoration and protection of cellular glycocalyx and a cell adhesion junction are provided. The use of the anisodamine or the pharmaceutically acceptable salt thereof in the preparation of cellular glycocalyx protectant also has an effect of protecting the structure and function of an endothelial cell.

This invention relates to an energy drug for treating mitochondrial damage under hypoxic conditions. The energy drug is the application of racemic scopolamine (Rac) in remodeling mitochondrial function. Hypoxic conditions include physiologically or pathologically induced hypoxia such as high altitude or vascular occlusion. This invention uses racemic scopolamine to treat hypoxic rat embryonic cardiomyocyte H9C2 and BALB / c mouse models, demonstrating that the compound has the characteristic of remodeling mitochondrial function under hypoxic conditions. It is a highly effective energy drug with promising clinical application prospects.